Masimo Co. (NASDAQ:MASI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Masimo Co. (NASDAQ:MASI) have been given an average recommendation of “Moderate Buy” by the six analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $191.40.

MASI has been the subject of a number of recent research reports. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, January 22nd. Wells Fargo & Company boosted their target price on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Piper Sandler boosted their target price on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Stifel Nicolaus restated a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Raymond James boosted their target price on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th.

Institutional Investors Weigh In On Masimo

A number of institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC grew its stake in Masimo by 5,340.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,394 shares of the medical equipment provider’s stock valued at $319,000 after acquiring an additional 2,350 shares during the period. State of Alaska Department of Revenue grew its stake in Masimo by 7.2% in the third quarter. State of Alaska Department of Revenue now owns 5,139 shares of the medical equipment provider’s stock valued at $685,000 after acquiring an additional 345 shares during the period. SteelPeak Wealth LLC acquired a new position in Masimo in the third quarter valued at about $570,000. Roubaix Capital LLC grew its stake in Masimo by 37.0% in the third quarter. Roubaix Capital LLC now owns 34,041 shares of the medical equipment provider’s stock valued at $4,539,000 after acquiring an additional 9,202 shares during the period. Finally, Malaga Cove Capital LLC acquired a new position in Masimo in the third quarter valued at about $401,000. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Trading Down 0.5 %

Shares of MASI opened at $179.43 on Thursday. The stock has a fifty day moving average price of $172.86 and a two-hundred day moving average price of $151.11. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo has a 52-week low of $101.61 and a 52-week high of $184.51. The company has a market cap of $9.61 billion, a price-to-earnings ratio of 123.74 and a beta of 1.02.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.